PriceTargets.com logo

Homology Medicines - FIXX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.75
  • Forecasted Upside: -19.76%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.93 As of 03/25/2024 05:00 PM ET
▲ +0.0071 (0.77%)

This chart shows the closing price for FIXX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Homology Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FIXX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FIXX

Analyst Price Target is $0.75
▼ -19.76% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Homology Medicines in the last 3 months. The average price target is $0.75, with a high forecast of $0.75 and a low forecast of $0.75. The average price target represents a -19.76% upside from the last price of $0.93.

This chart shows the closing price for FIXX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in Homology Medicines. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/28/2023Robert W. BairdDowngradeOutperform ➝ Neutral$4.50 ➝ $0.75Low
7/10/2023Chardan CapitalReiterated RatingBuyLow
4/6/2023FIXLower Target$9.50 ➝ $3.50Low
3/16/2023HC WainwrightReiterated RatingBuy$10.00Low
11/22/2022HC WainwrightReiterated RatingBuyLow
11/17/2022Chardan CapitalLower TargetBuy ➝ Buy$5.00 ➝ $4.00Low
11/16/2022Credit Suisse GroupLower Target$1.05N/A
11/11/2022Royal Bank of CanadaLower TargetSector Perform$2.00 ➝ $1.50Low
8/31/2022Robert W. BairdLower TargetOutperform ➝ Outperform$5.00 ➝ $4.50Low
8/16/2022Chardan CapitalLower TargetBuy ➝ Buy$7.00 ➝ $5.00Low
8/16/2022Credit Suisse GroupBoost TargetNeutral$1.55 ➝ $1.61Low
8/16/2022BTIG ResearchLower TargetBuy$14.50 ➝ $6.00Low
6/20/2022Credit Suisse GroupSet Target$1.55Low
5/23/2022HC WainwrightReiterated RatingBuy$10.00Medium
5/17/2022Chardan CapitalLower TargetNA$7.00High
5/17/2022Credit Suisse GroupLower TargetNeutral$1.05Low
4/28/2022Credit Suisse GroupInitiated CoverageNeutralLow
4/6/2022Canaccord Genuity GroupLower TargetBuy$9.50 ➝ $3.50High
4/6/2022FIXLower Target$9.50 ➝ $3.50High
3/29/2022Chardan CapitalReiterated RatingBuyHigh
3/22/2022Chardan CapitalReiterated RatingBuyLow
2/28/2022HC WainwrightLower TargetBuy$15.00 ➝ $10.00High
2/22/2022Bank of AmericaLower TargetBuy$12.50 ➝ $4.50High
2/22/2022BTIG ResearchLower TargetNeutral$17.50 ➝ $14.50High
2/22/2022Chardan CapitalLower TargetBuy$12.50 ➝ $7.50High
2/22/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$15.00 ➝ $2.00High
2/22/2022OppenheimerDowngradeOutperform ➝ Market PerformHigh
11/16/2021Chardan CapitalLower TargetBuy$15.00 ➝ $12.50High
9/7/2021OppenheimerReiterated RatingBuy$12.00Low
7/7/2021Chardan CapitalReiterated RatingBuyMedium
5/7/2021OppenheimerLower Target$13.50 ➝ $12.00Medium
3/1/2021Stifel NicolausInitiated CoverageHold$7.00High
12/14/2020HC WainwrightReiterated RatingBuy$15.00High
8/11/2020OppenheimerLower Target$16.00 ➝ $13.50Medium
8/11/2020HC WainwrightLower TargetBuy$18.50 ➝ $15.00High
8/10/2020Chardan CapitalReiterated RatingBuy$17.00High
6/25/2020Bank of AmericaInitiated CoverageBuy$15.00High
6/25/2020FIXInitiated CoverageBuy$15.00High
5/31/2020Chardan CapitalReiterated RatingBuy$17.00High
5/13/2020Royal Bank of CanadaInitiated CoverageOutperform$15.00High
3/16/2020FIXUpgradeMarket Perform ➝ OutperformHigh
3/15/2020OppenheimerUpgradeMarket Perform ➝ Outperform$16.00High
3/13/2020Chardan CapitalReiterated RatingBuy$17.00High
3/13/2020HC WainwrightReiterated RatingBuy$18.00High
3/13/2020Robert W. BairdBoost TargetOutperform$15.00 ➝ $16.00Low
2/24/2020Chardan CapitalInitiated CoverageBuy$17.00High
2/6/2020HC WainwrightReiterated RatingBuy$18.00Medium
11/1/2019OppenheimerInitiated CoverageMarket PerformHigh
10/31/2019FIXInitiated CoverageMarket PerformHigh
9/24/2019HC WainwrightSet TargetBuy$18.00High
9/9/2019Robert W. BairdInitiated CoverageOutperform$15.00High
6/11/2019HC WainwrightSet TargetBuy$18.00Medium
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Homology Medicines logo
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $0.93
Low: $0.90
High: $0.97

50 Day Range

MA: $0.51
Low: $0.30
High: $0.93

52 Week Range

Now: $0.93
Low: $0.46
High: $1.48

Volume

401,400 shs

Average Volume

390,307 shs

Market Capitalization

$54.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Homology Medicines?

The following equities research analysts have issued stock ratings on Homology Medicines in the last year: Chardan Capital, and Robert W. Baird.
View the latest analyst ratings for FIXX.

What is the current price target for Homology Medicines?

1 Wall Street analysts have set twelve-month price targets for Homology Medicines in the last year. Their average twelve-month price target is $0.75, suggesting a possible downside of 19.8%. Robert W. Baird has the highest price target set, predicting FIXX will reach $0.75 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $0.75 for Homology Medicines in the next year.
View the latest price targets for FIXX.

What is the current consensus analyst rating for Homology Medicines?

Homology Medicines currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for FIXX.

What other companies compete with Homology Medicines?

Other companies that are similar to Homology Medicines include Immuneering, Reneo Pharmaceuticals, SCYNEXIS, Vaxxinity and Kezar Life Sciences. Learn More about companies similar to Homology Medicines.

How do I contact Homology Medicines' investor relations team?

Homology Medicines' physical mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company's listed phone number is (781) 301-7277 and its investor relations email address is [email protected]. The official website for Homology Medicines is www.homologymedicines.com. Learn More about contacing Homology Medicines investor relations.